You are here

Matthew Rees


Rees MG, Seashore-Ludlow B, Cheah JH et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nature Chem Biol. 2016;12(2):109–116.

Seashore-Ludlow B, Rees MG, Cheah JH et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 2015;5(11):1210–1223.

Rees MG, Raimondo A, Wang J et al. Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum Mol Genet. 2014;23(20):5570–5578.

Matthew Rees, D.Phil.

Matthew Rees is a research scientist II in the Cancer Program under the direction of Cory Johannessen at the Broad Institute of MIT and Harvard, where he uses computational and experimental approaches to propose and test potential drug combinations, with the goal of identifying effective and safe combinations to use in the clinic. His research program centers on circumventing the emergence of drug resistance, which is a significant reason for the failure of cancer therapies.

Rees joined the Broad Institute in 2013 as a postdoctoral fellow in the laboratory of Stuart L. Schreiber before moving into a post as a staff scientist in the cancer program in 2015. He obtained his bachelor's degree, a masters in biochemistry, and D.Phil. in clinical medicine at the University of Oxford as a participant in the National Institutes of Health/University of Oxford IRTA fellowship program. In the course of his studies, he worked in the National Human Genome Research Institute in the laboratory of Francis S. Collins and the Oxford Centre for Diabetes, Endocrinology, and Metabolism at the University of Oxford, in the laboratories of Anna L. Gloyn and Mark I. McCarthy.

Contact Matthew Rees via email at

December 2016